170 related articles for article (PubMed ID: 21985267)
1. 90Y labeled phosphorodiamidate morpholino oligomer for pretargeting radiotherapy.
Liu G; Dou S; Liu Y; Wang Y; Rusckowski M; Hnatowich DJ
Bioconjug Chem; 2011 Dec; 22(12):2539-45. PubMed ID: 21985267
[TBL] [Abstract][Full Text] [Related]
2. Further investigations of morpholino pretargeting in mice--establishing quantitative relations in tumor.
Liu G; He J; Dou S; Gupta S; Rusckowski M; Hnatowich DJ
Eur J Nucl Med Mol Imaging; 2005 Sep; 32(9):1115-23. PubMed ID: 16133391
[TBL] [Abstract][Full Text] [Related]
3. Tumor pretargeting in mice using MORF conjugated CC49 antibody and radiolabeled complimentary cMORF effector.
Liu G; Dou S; Pretorius PH; Liu X; Chen L; Rusckowski M; Hnatowich DJ
Q J Nucl Med Mol Imaging; 2010 Jun; 54(3):333-40. PubMed ID: 20639818
[TBL] [Abstract][Full Text] [Related]
4. Predicting the biodistribution of radiolabeled cMORF effector in MORF-pretargeted mice.
Liu G; Dou S; He J; Liu X; Rusckowski M; Hnatowich DJ
Eur J Nucl Med Mol Imaging; 2007 Feb; 34(2):237-46. PubMed ID: 17021815
[TBL] [Abstract][Full Text] [Related]
5. A preclinical 188Re tumor therapeutic investigation using MORF/cMORF pretargeting and an antiTAG-72 antibody CC49.
Liu G; Dou S; Baker S; Akalin A; Cheng D; Chen L; Rusckowski M; Hnatowich DJ
Cancer Biol Ther; 2010 Oct; 10(8):767-74. PubMed ID: 21099368
[TBL] [Abstract][Full Text] [Related]
6. Pretargeting in tumored mice with radiolabeled morpholino oligomer showing low kidney uptake.
Liu G; He J; Dou S; Gupta S; Vanderheyden JL; Rusckowski M; Hnatowich DJ
Eur J Nucl Med Mol Imaging; 2004 Mar; 31(3):417-24. PubMed ID: 14691611
[TBL] [Abstract][Full Text] [Related]
7. Intraperitoneal injection is not always a suitable alternative to intravenous injection for radiotherapy.
Dou S; Smith M; Wang Y; Rusckowski M; Liu G
Cancer Biother Radiopharm; 2013 May; 28(4):335-42. PubMed ID: 23469942
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and in vitro characterization of a dendrimer-MORF conjugate for amplification pretargeting.
Chen X; Dou S; Liu G; Liu X; Wang Y; Chen L; Rusckowski M; Hnatowich DJ
Bioconjug Chem; 2008 Aug; 19(8):1518-25. PubMed ID: 18646837
[TBL] [Abstract][Full Text] [Related]
9. Tumor pretargeting in mice using (99m)Tc-labeled morpholino, a DNA analog.
Liu G; Mang'era K; Liu N; Gupta S; Rusckowski M; Hnatowich DJ
J Nucl Med; 2002 Mar; 43(3):384-91. PubMed ID: 11884499
[TBL] [Abstract][Full Text] [Related]
10. Radiolabeling of MAG3-morpholino oligomers with 188Re at high labeling efficiency and specific radioactivity for tumor pretargeting.
Liu G; Dou S; He J; Yin D; Gupta S; Zhang S; Wang Y; Rusckowski M; Hnatowich DJ
Appl Radiat Isot; 2006 Sep; 64(9):971-8. PubMed ID: 16730997
[TBL] [Abstract][Full Text] [Related]
11. Unexpected side products in the conjugation of an amine-derivatized morpholino oligomer with p-isothiocyanate benzyl DTPA and their removal.
Liu G; Dou S; Liu Y; Liang M; Chen L; Cheng D; Greiner D; Rusckowski M; Hnatowich DJ
Nucl Med Biol; 2011 Feb; 38(2):159-63. PubMed ID: 21315270
[TBL] [Abstract][Full Text] [Related]
12. Affinity enhancement pretargeting: synthesis and testing of a 99mTc-labeled bivalent MORF.
He J; Wang Y; Dou S; Liu X; Zhang S; Liu G; Hnatowich D
Mol Pharm; 2010 Aug; 7(4):1118-24. PubMed ID: 20507096
[TBL] [Abstract][Full Text] [Related]
13. Biodistribution and dosimetry of pretargeted monoclonal antibody 2D12.5 and Y-Janus-DOTA in BALB/c mice with KHJJ mouse adenocarcinoma.
Lubic SP; Goodwin DA; Meares CF; Song C; Osen M; Hays M
J Nucl Med; 2001 Apr; 42(4):670-8. PubMed ID: 11337558
[TBL] [Abstract][Full Text] [Related]
14. Replacing 99mTc with 111In improves MORF/cMORF pretargeting by reducing intestinal accumulation.
Liu G; Cheng D; Dou S; Chen X; Liang M; Pretorius PH; Rusckowski M; Hnatowich DJ
Mol Imaging Biol; 2009; 11(5):303-7. PubMed ID: 19326173
[TBL] [Abstract][Full Text] [Related]
15. Radiolabeling morpholinos with 90Y, 111In, 188Re and 99mTc.
Liu CB; Liu GZ; Liu N; Zhang YM; He J; Rusckowski M; Hnatowich DJ
Nucl Med Biol; 2003 Feb; 30(2):207-14. PubMed ID: 12623121
[TBL] [Abstract][Full Text] [Related]
16. Comparison between two labeled agents in mice using a coinjection-ratio approach in contrast to a conventional group approach.
Dou S; Wang Y; Barton B; Chen L; Rusckowski M; Shultz LD; Greiner DL; Liu G
Nucl Med Biol; 2014 Jan; 41(1):127-31. PubMed ID: 24210286
[TBL] [Abstract][Full Text] [Related]
17. Investigations of 99mTc morpholino pretargeting in mice.
Liu G; Liu C; Zhang S; He J; Liu N; Gupta S; Rusckowski M; Hnatowich DJ
Nucl Med Commun; 2003 Jun; 24(6):697-705. PubMed ID: 12766607
[TBL] [Abstract][Full Text] [Related]
18. Preparation of (111)In-DTPA morpholino oligomer for low abdominal accumulation.
Liu G; Dou S; Rusckowski M; Greiner D; Hnatowich D
Appl Radiat Isot; 2010 Sep; 68(9):1709-14. PubMed ID: 20359901
[TBL] [Abstract][Full Text] [Related]
19. Amplification targeting: a modified pretargeting approach with potential for signal amplification-proof of a concept.
He J; Liu G; Gupta S; Zhang Y; Rusckowski M; Hnatowich DJ
J Nucl Med; 2004 Jun; 45(6):1087-95. PubMed ID: 15181145
[TBL] [Abstract][Full Text] [Related]
20. Pretargeting CWR22 prostate tumor in mice with MORF-B72.3 antibody and radiolabeled cMORF.
Liu G; Dou S; Pretorius PH; Liu X; Rusckowski M; Hnatowich DJ
Eur J Nucl Med Mol Imaging; 2008 Feb; 35(2):272-80. PubMed ID: 17909792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
